Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma

The purpose of this study was to investigate the antitumor activity of regorafenib and sorafenib in preclinical models of HCC and to assess their mechanism of action by associated changes in protein expression in a HCC-PDX mouse model. Both drugs were administered orally once daily at 10 mg/kg (rego...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncotarget
Hoofdauteurs: Kissel, Maria, Berndt, Sandra, Fiebig, Lukas, Kling, Simon, Ji, Qunsheng, Gu, Qingyang, Lang, Tina, Hafner, Frank-Thorsten, Teufel, Michael, Zopf, Dieter
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Impact Journals LLC 2017
Onderwerpen:
Research Paper
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5739799/
https://ncbi.nlm.nih.gov/pubmed/29291014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22334
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items